Navigation Links
Some bisphosphonates users unfamiliar with drug's possible side effects on oral health
Date:5/26/2010

CHICAGO, May 26, 2010 People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of the Journal of the American Dental Association (JADA).

Use of bisphosphonates has been associated with a small risk of developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously or after the patient has undergone dental surgery. BON is a rare but serious condition that can cause severe damage to the jaw bone. The prevalence of BON is between three and 12 percent for patients who receive bisphosphonates intravenously for cancer therapy and less than one percent for patients who receive bisphosphonates orally for osteoporosis or osteopenia.

In the study, the authors sought to determine whether patients taking bisphosphonates had knowledge about the medical indication for the therapy and how long the treatment would last. They also wanted to know whether participants' physicians told them about possible adverse reactions.

The researchers interviewed 73 participants (71 women, two men) seeking routine care in a dental clinic. These participants, with an average age of 66 years that ranged from 44 to 88 years, also were undergoing bisphosphonate treatment. Eighty-four percent of the participants stated they knew why they were receiving bisphosphonate therapy. However, 80 percent said they were unsure about the duration of the therapy and 82 percent could not recall receiving information about the risk of experiencing adverse reactions, including oral osteonecrosis, by their physicians.

"The results of our small study show that patients who take bisphosphonates may not be aware that BON can develop after they undergo invasive dental care," the authors wrote. "We believe that a more effective communication process between prescribing physicians, dentists and patients using bisphosphonates is needed."

The American Dental Association Advisory Committee on Medication-induced Osteonecrosis of the Jaw recommends that dental patients on bisphosphonate therapy advise their dentist. The Committee believes that it is always appropriate for physicians to encourage patients to visit the dentist regularly for professional cleanings and oral exams, as recommended by their dentist. This is especially important for patients whose oral health is put at risk from medications or medical problems.


'/>"/>

Contact: Fred Peterson
petersonf@ada.org
American Dental Association
Source:Eurekalert

Related medicine news :

1. Salesforce CRM Users Outperform Past Results by a Factor of at Least 50%
2. Hissey Kientz, LLP Warns Birth Control Pill Users Of Increased Health Risks To Those Who Have Or Are Taking YAZ or YASMIN
3. Male Abusers Often Sabotage Birth Control With Partners
4. New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s
5. Ecstasy Users at Higher Risk of Sleep Apnea
6. New AERIUS Cell Phones Direct Microwave Signals Away from Users
7. Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil
8. Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users
9. Brain scan study shows cocaine abusers can control cravings
10. Technology new gateway into treatment for problem alcohol users: Study
11. Phonak Asks Young FM Users to Tell Their Stories on YouTube
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... ... Driving Dynamics Inc., announced today it has been selected as a 2017 ... its mission to continually monitor the training marketplace for the best providers of training ... and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out ... organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 ... with a deadline of September 2018. , As described in this ...
(Date:9/19/2017)... ... ... Bone Solutions Inc. (BSI), an orthobiologics technology company located ... OsteoCrete® bone void filler is designed to assist with bone repair and generation, ... for bone health and development. , “We’re excited to bring this important orthopedic ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Davidson Institute for Talent ... on September 27 at a reception in Washington D.C. The recipients received $50,000, ... Music. , “I am honored to be a Davidson Fellow Laureate,” said Rishab ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology: